Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C4463415!4463415!26085947     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Naturae 2015 ; 7 (2): 74-9 Nephropedia Template TP {{tp|p=26085947|t=2015. Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting |pdf=|usr=}}{{26085947}} gab.com Text Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting JO: Acta Naturae http://www.kidney.de/pget.php?&tw=1&pmid=26085947 #FOAvip B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders. Twit Text FOAVip Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting ????Acta Naturae http://www.kidney.de/pget.php?&tw=1&pmid=26085947 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26085947 #FOAvip English Wikipedia <ref>{{Cite pmid|26085947}}</ref> Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting #MMPMID26085947 Stepanov AV; Belogurov Jr. AA; Kothapalli P; Shamborant OG; Knorre VD; Telegin GB; Ovsepyan AA; Ponomarenko NA; Deyev SM; Kaveri SV; Gabibov AG Acta Naturae 2015[Apr]; 7 (2): 74-9 PMID26085947show ga B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders. äSpecific Depletion of Myelin-Reactive B Cells via BCR-Targeting (epmc).pdf DeepDyve Pubget Overpricing